Insider Selling: ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Sells $243,106.78 in Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Mark Schneyer sold 10,262 shares of the stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $23.69, for a total value of $243,106.78. Following the sale, the executive vice president owned 53,338 shares in the company, valued at $1,263,577.22. The trade was a 16.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

ACADIA Pharmaceuticals Stock Up 2.9%

Shares of ACAD opened at $23.56 on Friday. The business has a fifty day moving average of $22.33 and a 200 day moving average of $22.51. The company has a market cap of $3.99 billion, a PE ratio of 17.71, a P/E/G ratio of 7.90 and a beta of 0.80. ACADIA Pharmaceuticals Inc. has a 52-week low of $13.40 and a 52-week high of $26.65.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.28. ACADIA Pharmaceuticals had a net margin of 21.80% and a return on equity of 14.69%. The business had revenue of $278.63 million for the quarter, compared to the consensus estimate of $276.52 million. During the same quarter in the prior year, the firm posted $0.20 earnings per share. The business’s revenue for the quarter was up 11.3% on a year-over-year basis. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Geneos Wealth Management Inc. raised its holdings in shares of ACADIA Pharmaceuticals by 113.0% in the third quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 756 shares in the last quarter. Smartleaf Asset Management LLC increased its position in ACADIA Pharmaceuticals by 107.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 885 shares during the period. USA Financial Formulas bought a new stake in shares of ACADIA Pharmaceuticals in the 3rd quarter valued at about $41,000. Picton Mahoney Asset Management bought a new stake in shares of ACADIA Pharmaceuticals in the 1st quarter valued at about $32,000. Finally, Banque Transatlantique SA purchased a new stake in shares of ACADIA Pharmaceuticals in the 1st quarter worth approximately $31,000. Institutional investors own 96.71% of the company’s stock.

Analyst Upgrades and Downgrades

ACAD has been the subject of several recent analyst reports. JPMorgan Chase & Co. dropped their target price on ACADIA Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating for the company in a research report on Monday, November 17th. The Goldman Sachs Group boosted their price objective on ACADIA Pharmaceuticals from $15.00 to $17.00 and gave the company a “sell” rating in a report on Thursday, August 7th. Needham & Company LLC upped their price objective on ACADIA Pharmaceuticals from $28.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Mizuho lifted their target price on ACADIA Pharmaceuticals from $23.00 to $24.00 and gave the stock a “neutral” rating in a research report on Thursday, August 7th. Finally, Royal Bank Of Canada lowered their target price on shares of ACADIA Pharmaceuticals from $34.00 to $32.00 and set an “outperform” rating for the company in a research note on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $28.83.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.